Discontinued — last reported Q2 '23

Other Income & Expense

Net Unrealized Gain on Equity Securities

Year-over-year, this metric declined by 100.0%, from $750.00K to $0.00. This is a positive signal — higher values indicate stronger performance for this metric.

Analysis

StatementIncome Statement
SectionOther Income & Expense
CategoryProfitability
SignalHigher is better
VolatilityVolatile
First reportedQ2 2023
Last reportedQ2 2023

How to read this metric

Positive values indicate favorable market performance of the company's investment holdings.

Detailed definition

This metric reflects the increase in the fair market value of equity investments held by the company that have not yet b...

Peer comparison

Common for companies with large treasury or venture investment portfolios.

Metric ID: is_gild_net_unrealized_gain_on_equity_securities

Historical Data

8 periods
 Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
Value$750.00K$750.00K$750.00K$750.00K$3.00M-$3.00M$0.00$0.00
QoQ Change+0.0%+0.0%+0.0%+300.0%-200.0%+100.0%
YoY Change+300.0%-500.0%-100.0%-100.0%
Range-$3.00M$3.00M
CAGR-100.0%
Avg YoY Growth-100.0%
Median YoY Growth-100.0%

Frequently Asked Questions

What is Vertex Pharmaceuticals's net unrealized gain on equity securities?
Vertex Pharmaceuticals (VRTX) reported net unrealized gain on equity securities of $0.00 in Q4 2025.
How has Vertex Pharmaceuticals's net unrealized gain on equity securities changed year-over-year?
Vertex Pharmaceuticals's net unrealized gain on equity securities decreased by 100.0% year-over-year, from $750.00K to $0.00.
What does net unrealized gain on equity securities mean?
Profit from the increase in value of stock investments that have not been sold yet.